ArticleEcancermedicalscience2008
Cardio-oncology: a new medical issue.
Article in Ecancermedicalscience, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Comparative Analysis of Speckle-tracking Echocardiography and Cardio-specific Markers for Early Detection of Cardiotoxicity in Patients With Breast Cancer.Journal of the Saudi Heart Association · 2025Article
- Cancer and Cardiovascular Disease: The Conjoined Twins.Cancers · 2024Review
- Home-based self-management multimodal cancer interventions & cardiotoxicity: a scoping review.Cardio-oncology (London, England) · 2024Article
- The cardio-oncology continuum: Bridging the gap between cancer and cardiovascular care.Global cardiology science & practice · 2024Review
- Ferroptosis-induced Cardiotoxicity and Antitumor Drugs.Current medicinal chemistry · 2024Review
- Review
- The European Society of Cardiology Cardio-Oncology Guidelines: Evidence Base, Actionability, and Relevance to Clinical Practice.JACC. CardioOncology · 2023Article
- Effect of Danshen for improving clinical outcomes in patients with bladder cancer: a retrospective, population-based study.Frontiers in pharmacology · 2023Article
- Long-term cardiovascular mortality risk in patients with bladder cancer: a real-world retrospective study of 129,765 cases based on the SEER database.Frontiers in cardiovascular medicine · 2023Article
- Understanding the Protective Role of Exosomes in Doxorubicin-Induced Cardiotoxicity.Oxidative medicine and cellular longevity · 2022Review
- Relevance of Ferroptosis to Cardiotoxicity Caused by Anthracyclines: Mechanisms to Target Treatments.Frontiers in cardiovascular medicine · 2022Review
- Cardiogenic shock among cancer patients.Frontiers in cardiovascular medicine · 2022Review
- Cardiac risk stratification of breast cancer patients in a cardio-oncology clinic.Breast cancer research and treatment · 2021Article
- High-sensitivity cardiac troponin T determines all-cause mortality in cancer patients: a single-centre cohort study.ESC heart failure · 2021Article
- Radiation-Association Hypertension in Patients Undergoing Treatment for Prostate Cancer.Journal of radiotherapy in practice · 2020Article
- Fatal heart disease among cancer patients.Nature communications · 2020Article
- Cardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients: a prospective study.Cancer communications (London, England) · 2018Article
- Rationale for setting up a cardio-oncology unit: our experience at Mayo Clinic.Cardio-oncology (London, England) · 2016Review
- Cardiovascular Risk and Level of Statin Use Among Women With Breast Cancer in a Cardio-Oncology Clinic.Ochsner journal · 2016Article
- Evaluation and management of patients with heart disease and cancer: cardio-oncology.Mayo Clinic proceedings · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to the increasing number of long-term cancer survivors, the ageing of the population, as well as the increased incidence and prevalence of oncologic and cardiovascular diseases, the number of patients presenting oncologic and cardiologic co-morbidities are increasing. Accordingly, there is a rapidly growing need for a comprehensive and proficient management of patients in whom the two co-morbidities exist, and for cancer patients whose clinical history and oncologic treatment put them at higher risk for developing cardiovascular problems, in order to provide the optimal treatment in every situation, and to avoid the possibility that the development of the second disease does not lead to a reduction of therapeutic opportunities for the patient. A new discipline, cardio-oncology, has been created to deal with this need. Its aim is to investigate new strategies, collect new evidence-based indications and develop interdisciplinary expertise in order to manage this growing category of patients. Cardio-oncology deals with the following main clinical and research areas: early diagnosis of cardiotoxicity, risk stratification and preventions, treatment and monitoring of cardiotoxicity.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.